Fig. 1 · Structure

Documents & Downloads

Acipimox

Cat. No. A10033 CAS 51037-30-0

Antilipolytic agent

Acipimox is a niacin derivative used as a hypolipidemic agent.

In Stock

Publications for Acipimox

1 publication citing this product

  1. A. Geneste, .et al. , BMC Pharmacol Toxicol, 2020, 21: 61 PMID: 32795383

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Acipimox activates HCAR2-linked Gi/o signaling. In HEK293 cells expressing human HCAR2, it reduced forskolin-stimulated cAMP in a concentration-response assay. [1]

Acipimox also inhibits recombinant human carbonic anhydrases in a cell-free assay. Reported Ki values were 2.8–9.2 μM for the tested isoforms other than hCA XIII, which had a Ki of 87 μM. These results do not establish cellular carbonic anhydrase engagement. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Acipimox Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Acipimox from 4 published references. In vitro models include HEK293 cells transiently expressing wild-type human HCAR2.

Acipimox In Vitro Studies

In an adipocyte-conditioned-medium model, exposure of adipocytes to 100 μM acipimox for 6 h reduced the subsequent protective effect of their medium on lapatinib-treated BT-474 cells. This indirect assay does not establish acipimox monotherapy activity against breast cancer cells. [3]

HCAR2-linked cAMP response

Cell-based study · HEK293 cells transiently expressing wild-type human HCAR2 [1]

Acipimox reduced forskolin-stimulated cAMP in the wild-type HCAR2 concentration-response experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Forskolin-stimulated intracellular cAMPQualitative concentration response Reduced with increasing acipimox concentration; mean ± SEM; experiments performed in triplicate[1]

Literature-Reported Treatment Conditions

Exposure duration
30 min agonist stimulation at 37 °C
Method
Cellular concentration-response assay
Co-treatment
20 μM forskolin and 500 μM IBMX during agonist stimulation
Reported limits
Exact tested concentration series and acipimox vehicle are not stated in the main cAMP assay methods. Triplicate is not identified as biological versus technical replication.
Methods and source locations

Compound reported in the paper: Acipimox; Compound label in the paper: Acipimox

Receptor-expressing cell assay; no recommended concentration, clinical effect or absolute receptor selectivity inferred.

Results: Ligand recognition of HCAR2; Figure 2a,i and caption; Materials and methods: cAMP assay

Forskolin-stimulated intracellular cAMP: Gi/o cAMP fluorescence assay — Results: Ligand recognition of HCAR2; Figure 2a,i and caption; Materials and methods: cAMP assay

Inhibition of recombinant human carbonic anhydrases

Biochemical assay · Recombinant human carbonic anhydrase isoforms I, II, III, IV, VA, VB, VI, VII, IX, XII, XIII and XIV [2]

Acipimox inhibited CO2 hydration by the tested human carbonic anhydrases, with weaker inhibition of hCA XIII.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CO2 hydration by human carbonic anhydrasesKi hCA I: 3.3; II: 7.5; III: 5.4; IV: 8.8; VA: 7.5; VB: 2.8; VI: 7.0; VII: 9.2; IX: 6.3; XII: 8.4; XIII: 87; XIV: 5.9 μM[2]
Replicate and uncertainty descriptionReported precision Mean from 3 different assays; errors ± 5–10% of reported values (data not shown)[2]

Literature-Reported Treatment Conditions

Exposure duration
15 min enzyme–inhibitor preincubation; initial rates followed for 10–100 s
Method
Stopped-flow assay; 10 mM HEPES, pH 7.4; CO2 substrate 1.7–17 mM
Vehicle
Stock solutions in distilled-deionized water with maximum 5% DMSO; subsequent assay-buffer dilutions
Reported limits
Final DMSO percentage and full inhibitor concentration series are not explicitly reported. Ki values are measurements, not treatment recommendations.
Methods and source locations

Compound reported in the paper: Acipimox; Compound label in the paper: Acipimox

Cell-free inhibition only; no cellular target engagement or antiobesity efficacy inferred.

Sections 2.2 Carbonic anhydrase inhibition, 2.3 Chemicals, 3.1 CA inhibition; Table 1, compound 1 column and footnote

CO2 hydration by human carbonic anhydrases: Stopped-flow CO2 hydration assay; uncatalyzed rates subtracted; nonlinear least squares and Cheng–Prusoff analysis — Sections 2.2 Carbonic anhydrase inhibition, 2.3 Chemicals, 3.1 CA inhibition; Table 1, compound 1 column and footnote

Replicate and uncertainty description: Table footnote does not define the error as SD or SEM — Table 1 footnote

Adipocyte-conditioned medium and lapatinib response

Cell-based study · Differentiated murine 3T3-F442A adipocytes (#3T3) and human BT-474 breast cancer cells [3]

Conditioned medium from acipimox-exposed adipocytes produced a lower lapatinib IC50 in BT-474 cells than conditioned medium from untreated adipocytes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lapatinib response after transfer of adipocyte-conditioned mediumQualitative IC50 comparison Lower lapatinib IC50 with acipimox-conditioned medium than with untreated adipocyte-conditioned medium; n ≥ 3[3]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM acipimox applied to adipocytes
Exposure duration
6 h adipocyte conditioning; BT-474 cells subsequently exposed to lapatinib for 72 h
Method
Conditioned-medium transfer followed by MTT assay
Co-treatment
Lapatinib concentration-response in recipient BT-474 cells; acipimox applied during adipocyte conditioning
Reported limits
Acipimox vehicle, residual drug carryover and exact lapatinib concentration series are not specified for Figure 6B. No numeric IC50 or acipimox-specific significance is inferred from the bars.
Methods and source locations

Compound reported in the paper: Acipimox; Compound label in the paper: Acipimox

Indirect conditioned-medium assay; not evidence of acipimox monotherapy cytotoxicity, identified soluble mediators or in vivo anticancer efficacy.

Methods: Cell culture, Cytotoxicity MTT assay, Statistical analysis, Materials; Results Sec18; Figure 6B and caption

Lapatinib response after transfer of adipocyte-conditioned medium: MTT readout after lapatinib exposure; IC50 calculated using Compusyn — Methods: Cell culture, Cytotoxicity MTT assay, Statistical analysis, Materials; Results Sec18; Figure 6B and caption

Acipimox In Vivo Studies

In male Sprague Dawley rats, acipimox at 50 mg/kg/day by oral gavage for 7 days did not improve muscle mass or gastrocnemius protein balance after burn injury. Acipimox was associated with greater body-weight loss. Food intake was not measured, limiting interpretation of the weight change. [4]

No muscle-protection benefit in a rat burn model

Animal study · Male Sprague Dawley rats randomized to ~60% total body-surface area scald burn or sham and acipimox or PBS; 48 animals assigned [4]

Seven days of acipimox did not improve measured muscle mass or gastrocnemius protein balance in this model and was associated with greater body-weight loss.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Muscle wet weights, gastrocnemius triglycerides and muscle protein kineticsReported null findings No significant acipimox effect on examined muscle wet weights, gastrocnemius triglyceride concentration or protein kinetics[4]
Body-weight changeANOVA Main effects of burn and acipimox: both P < 0.001; burn × acipimox interaction: P = 0.008[4]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Daily
Treatment course
7 days
Vehicle
Phosphate buffered saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Acipimox versus vehicle in burn and sham groups
50 mg.kg b.w.−1.day−1
Vehicle-treated burn and sham groupsNo improvement in examined muscle wet weights, gastrocnemius triglyceride content or protein kinetics. Body-weight loss was greater with acipimox.[4]
Acipimox versus vehicle in burn and sham groups
Model: Male Sprague Dawley rats; ~60% total body-surface area scald burn or sham; n = 12 assigned per injury × treatment group
Reported limits: One burn-acipimox animal was euthanized before day 7; final endpoint-specific n after exclusions is not tabulated in the selected text. Food intake was not measured.
Methods and source locations

Compound reported in the paper: Acipimox; Compound label in the paper: Acipimox

Model-specific negative outcome; no general lack of antilipolytic activity or cross-species dose equivalence inferred.

Materials and methods: Animals and Statistics; Results paragraphs and Figures 1–3 captions; Discussion limitations

Muscle wet weights, gastrocnemius triglycerides and muscle protein kinetics: Tissue weighing, triglyceride assay and heavy-water-based protein kinetics; two-way ANOVA — Results; Figure 1B–E, Figure 2 and Figure 3 captions

Body-weight change: Repeated body-weight assessment; three-way ANOVA and follow-up two-way ANOVAs — Results first paragraph; Statistics

Acipimox versus vehicle in burn and sham groups · Materials and methods: Animals and Statistics; Results paragraphs and Figures 1–3 captions; Discussion limitations

Specifications

Manufacturer Adooq Bioscience
CAS Number 51037-30-0
Applications Antilipolytic agent
Formula C6H6N2O3
Molecular Weight 154.1
Synonyms K-9321; Olbemox; Olbetam
SMILES
CC1=CN=C(C=[N+]1[O-])C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 29 mg/mL (188.16 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Acipimox Research References

  1. [1] Pan X, Ye F, Ning P, et al. Structural insights into ligand recognition and selectivity of the human hydroxycarboxylic acid receptor HCAR2 Cell discovery (2023). PMID: 38012147 DOI: 10.1038/s41421-023-00610-7 Source material
  2. [2] Mori M, Supuran CT. Acipimox inhibits human carbonic anhydrases Journal of enzyme inhibition and medicinal chemistry (2022). PMID: 35139721 DOI: 10.1080/14756366.2022.2037579 Source material
  3. [3] Geneste A, Duong MN, Molina L, et al. Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib BMC pharmacology & toxicology (2020). PMID: 32795383 DOI: 10.1186/s40360-020-00436-z Source material
  4. [4] Vardarli E, Bhattarai N, El Ayadi A, et al. Burns results in profound muscle protein wasting in Sprague Dawley rats that is not resolved using the lipolysis inhibitor, acipimox PloS one (2025). PMID: 40392906 DOI: 10.1371/journal.pone.0323640 Source material

Publications

1 publication citing this product

  1. A. Geneste, .et al. , BMC Pharmacol Toxicol, 2020, 21: 61 PMID: 32795383

Added to your cart

View Cart Checkout
Loading...